Taysha Gene Therapies Posts Wider Q1 Net Loss
08:26 AM EDT, 05/11/2021 (MT Newswires) -- Taysha Gene Therapies (TSHA) on Tuesday reported a Q1 net loss of $0.87 per share, compared with $0.50 loss per share a year ago. Analysts polled by Capital IQ had called for $0.64 loss per share.
The gene therapy company said it ended Q1 with $228.7 million of cash, and cash equivalents, which is expected to support planned operations into 2023.
The company did not report revenue for the quarter, in line with expectations.
Price: 20.52, Change: -0.68, Percent Change: -3.21